Results 171 to 180 of about 7,868,209 (310)
The Bold Surgeon Syndrome: Contemporary Analysis of Overconfidence, Training Gaps, and Patient Safety in Plastic Surgery. [PDF]
Cárdenas-Camarena L +4 more
europepmc +1 more source
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension phase).
Fabrizio De Benedetti +19 more
wiley +1 more source
WHO five moments for medication safety among diabetic patients in Saudi Arabia. [PDF]
ElZayat A +5 more
europepmc +1 more source
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner +14 more
wiley +1 more source
Fundamental safety-capability trade-offs in fine-tuning large language models. [PDF]
Chen PY, Shen H, Das P, Chen T.
europepmc +1 more source
Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring
Annals of Clinical and Translational Neurology, EarlyView.
Francesco Saccà, Ryan Pelto
wiley +1 more source
Objective We evaluated the role of 25‐hydroxyvitamin D (25[OH]D), prednisone, and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25(OH)D levels and other potential risk factors and BMD measures (spine T scores) and osteoporosis (defined as a T ...
Nima Madanchi +4 more
wiley +1 more source
Conclusion on the peer review of the pesticide risk assessment of the active substance blood meal
European Food Safety Authority
doaj +1 more source
Opportunities and Challenges of Using Big Data to Detect Drug-Drug Interaction Risk [PDF]
Chasioti D. +1 more
core +1 more source

